Cadila Healthcare Ltd has received tentative approval from US FDA to market its antibiotic, Gatifloxacin tablets, 200 mg and 400 mg, in the US market.
The move comes after international studies revealed that Gatifloxacin posed 17 times higher risk of developing serious hyperglycemia than other antibiotics in elderly patients.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances